Licensing Momentum NOX-A12 already has a collaboration with Merck/MSD for combination with KEYTRUDA in pancreatic and colorectal cancers, and the regulatory path includes FDA Fast Track designation for NOX-A12 in glioblastoma along with a designed randomized Phase two trial, signaling strong licensing or co‑development potential with other major pharma to expand indications and regimens that target the tumor microenvironment.

GBM Growth Lead asset NOX-A12 targets glioblastoma with promising topline signals and shows synergy with radiotherapy and bevacizumab, creating avenues to partner with neuro-oncology networks and trial sites for expanded GBM programs.

Leadership Momentum New CEO appointed early in 2025 coupled with ongoing fundraising activity indicates a deliberate push to accelerate business development and secure strategic partnerships to advance the NOX-A12 program and other Spiegelmer assets.

Regulatory Window Regulatory momentum creates a near-term sales window: FDA Fast Track designation and BfArM involvement in trial design can help trigger milestone-based deals, upfronts, and risk-sharing partnerships with potential licensees.

Asset Portfolio Beyond NOX-A12, the pipeline includes NOX-E36 and other Spiegelmer assets, offering multi-indication collaboration opportunities and the potential to license across different tumor microenvironment targets.